Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate Meeting Abstract
| Authors: | Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; Liu, T.; Tehfe, M.; Elimova, E.; Bruges, R.; Cleary, J. M.; Karamouzis, M.; Soleymani, S.; Lei, M.; Chanaga, C. A.; Ajani, J. A. |
| Abstract Title: | Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate |
| Meeting Title: | 36. Deutscher Krebskongress - Fortschritt gemeinsam gestalten |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Feb 21-24 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2024-02-01 |
| Start Page: | 64 |
| Language: | English |
| ACCESSION: | WOS:001332646400150 |
| PROVIDER: | wos |
| DOI: | 10.1159/000535363 |
| Notes: | Meeting Abstract: 70 -- 'The 36th German Cancer Congress - Building Progress Together' -- Located in the section 'Gastrointestinal Cancer: other than colorectal' -- Source: Wos |
